EIT-DIGITAL-ACCELERATOR
23.4.2020 15:02:06 CEST | Business Wire | Press release
The EIT Digital Challenge , the competition for European digital deep tech companies, is now accepting applications. Fast-growing startups with existing customers – so called scaleups – are invited to apply in one of the following five thematic areas: Digital Tech, Digital Cities, Digital Industry, Digital Wellbeing and Digital Finance. The best five companies will receive prizes totaling €350,000 in cash and in kind. The application deadline is 7 June 2020.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200423005447/en/
“Among all applicants to the competition, we will select 20 companies and invite them to an exclusive event in November where they will pitch to a jury of high-profile corporates and investors,” says Dolf Wittkamper, Head of the EIT Digital Accelerator . “A total of 5 winners will be announced during this event, one Challenge winner and four runners-up; they all will receive a full year of tailored support from the EIT Digital Accelerator, valued at €50,000. On top of that, the Challenge winner will receive a cash prize of €100,000.”
The competition is focusing on ‘deep tech’ scaleups, broadly defined as technology companies with a differentiating product offering, leveraging sophisticated technology which is often protected or hard to reproduce.
“To overcome the current crisis, we need the imagination and the execution of the best entrepreneurs out there. With the EIT Digital Challenge, we are determined to identify the best European deep tech entrepreneurs and support them in building major companies that will tackle the world’s major challenges,” EIT Digital’s Chief Innovation Officer, Chahab Nastar, says.
Being awarded by the EIT Digital Challenge represents a significant milestone for scaleups willing to grow and expand internationally.
“Winning the EIT Digital Challenge helped us seize a couple of major deals for which we were waiting for the clients' final decisions. In less than 6 months, EIT Digital has already proved to provide us huge media coverage, some welcome financial support as well as numerous sales opportunities in Europe for which we are very grateful”- says Lucas Le Bell, CEO and Co-Founder of CerbAir, who was awarded in 2019 and joined the EIT Digital Accelerator shortly after.
The EIT Digital Accelerator consists of a pan-European team of business developers and fundraising experts operating from 17 cities across Europe, along with a hub in Silicon Valley. Since 2012, the EIT Digital Accelerator has supported over 300 fast-growing startups to sign up customers and raise capital. In 2019, the EIT Digital Accelerator was ranked among the World’s Top 5 Public Business Accelerators by UBI Global, and one of the top Accelerator brands in Europe, according to a survey by the European Startup Initiative.
Application criteria
To apply for the EIT Digital Challenge, companies must fulfil the following criteria: they must be based in one of the member states of the European Union, United Kingdom, or in one of the Horizon 2020 associated countries , they have to be in the growth stage (to be proven by showing annual revenue of over €300,000 or at least €2m in total funding), and they should be in their first ten years of existence.
Since its launch in 2014, the competition has attracted more than 2000 entries from all over Europe. Most of the winning scaleups have gone on to become internationally successful companies. Now it’s your turn!
The deadline for applications is 7 June 2020. For further information and to apply, please visit www.challenge.eitdigital.eu
View source version on businesswire.com: https://www.businesswire.com/news/home/20200423005447/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Carnegie Mellon University and Cleveland Clinic Develop AI System to Interpret Cardiac MRI Scans with Enhanced Accuracy21.5.2026 14:05:00 CEST | Press release
Trained on more than 13,000 patient studies, novel system significantly outperforms existing models by up to 35% A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521762286/en/ A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. The novel system, called CMR-CLIP, is d
Otovo Hits 30,000 Customers in Under a Year, Tackling the Growing ‘Solar Service Crisis’21.5.2026 14:00:00 CEST | Press release
A growing wave of unsupported solar systems and rising electricity prices are creating strong demand for Otovo’s energy service platform Otovo ASA (“Otovo”), a leading global energy service provider for residential and commercial customers, today announced it has reached 30,000 customers across the U.S. and Europe. A total of 20,000 customers have enrolled in Otovo Care, the Company’s membership-based home and commercial energy service, which is powered by Otovo’s industry-leading AI platform, Endurance™. “Reaching 30,000 customers in less than year is proof positive that home and business owners value their power systems,” said William J. (John) Berger, CEO of Otovo. “The ‘solar service crisis’ that is leaving millions of orphaned energy systems without support is driving strong interest in our Otovo Care membership program. Every day your home or commercial power system is not working, you are throwing money away. Otovo’s rapid response service platform keeps you up and running, ensu
The Live Moment Effect: Genius Sports and MediaScience Study Finds Specific Moments in Live Sports Can Double Unaided Brand Recall21.5.2026 14:00:00 CEST | Press release
New research shows that brands aligned with emotionally heightened moments in live sports can improve ad effectiveness Genius Sports Limited (NYSE: GENI), a global leader in real-time sports data, today released new biometric research conducted with MediaScience showing that ads delivered immediately after emotionally heightened moments in live sports can double unaided brand recall. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521475265/en/ The Live Moment Effect report from Genius Sports and MediaScience. The study, The Live Moment Effect, finds that advertising effectiveness is significantly influenced by a viewer’s emotional state immediately before an ad is shown. In controlled biometric testing, ads shown after high-intensity sporting moments, such as near-scoring plays or crucial momentum shifts, delivered approximately double the unaided brand recall of baseline conditions. The Moment Before the Ad Matters The r
Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer21.5.2026 14:00:00 CEST | Press release
Precemtabart tocentecan (Precem-TcT) is investigated as a potential first-in-class anti-CEACAM5 ADC, for the treatment of metastatic CRC (mCRC) CEACAM5 is overexpressed in the majority of colorectal tumors (~90%), and requires no patient selection Significant unmet need remains for clinically meaningful innovation in colorectal cancer (CRC), the second leading cause of cancer death worldwide Not intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced that the first patient has been dosed in the Phase 3 PROCEADE®-CRC-03 trial (NCT07549412). The study is evaluating precemtabart tocentecan (Precem‑TcT), a potential first‑in‑class investigational anti‑CEACAM5 antibody‑drug conjugate (ADC), for the treatment of metastatic colorectal cancer (mCRC). “Leveraging our novel payload‑linker technology, Precem‑TcT is the first CEACAM5‑targeted ADC in clinical studies with an exatecan payload, rationally designed for stability and enhanced cancer
Baszucki Group Funds Oxford University Clinical Trial of Ketogenic Therapy for Early Psychosis21.5.2026 13:00:00 CEST | Press release
Randomized controlled trial will evaluate both symptom progression and underlying biology Baszucki Group today announced a £1.17 million grant to support a randomized controlled trial at the University of Oxford assessing the feasibility, safety, and efficacy of a ketogenic diet for patients at clinical high risk of psychosis (CHR-P). Researchers will test this nutritional therapy's ability to improve patients' mental and physical health. This project builds on a growing body of research suggesting the potential of metabolic therapies in treating serious mental illness. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521877110/en/ Baszucki Group Funds £1.17 Million for University of Oxford Trial of Ketogenic Therapy for Early Psychosis Psychotic disorders carry a massive personal burden and are associated with a lower life expectancy. Psychosis does not develop immediately, but typically emerges following a period of early
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
